Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 2/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604080 | 0.99 | L3MBTL1 (0.33) | L3MBTL1SLC1A3SLC1A2SLC1A1KDM4E | |
| SCHEMBL8233820 | 0.84 | HTR2C (0.36) | EPHX1 | |
| SCHEMBL3595027 | 0.77 | SLC6A2 (0.38) | L3MBTL1ALDH1A1KDM4EMETAP2EPHX1 | |
| SCHEMBL3603986 | 0.77 | SLC6A2 (0.38) | L3MBTL1ALDH1A1KDM4EMETAP2EPHX1 | |
| SCHEMBL1870673 | 0.75 | SLC6A2 (0.36) | L3MBTL1ALDH1A1KDM4EMETAP2EPHX1 | |
| SCHEMBL5318798 | 0.68 | PIK3CD (0.31) | — | |
| SCHEMBL4436354 | 0.68 | PIK3CD (0.31) | — | |
| SCHEMBL3338710 | 0.66 | GPR88 (0.41) | SLC1A3SLC1A2SLC1A1METAP2 | |
| SCHEMBL3338713 | 0.66 | GPR88 (0.41) | SLC1A3SLC1A2SLC1A1METAP2 | |
| SCHEMBL3607510 | 0.66 | GPR88 (0.41) | SLC1A3SLC1A2SLC1A1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | L3MBTL1 3699/4885SLC1A3 395/4885SLC1A2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.